UP!

CDXS $12.03   View long term graphs

Codexis, Inc.
Type
Public
Traded as NASDAQ: CDXS
Industry protein engineering, biocatalysis, pharmaceuticals, biotherapeutics, industrial biotechnology, fine chemicals
Founded 2002
Headquarters Redwood City, CA, U.S.,
Key people
  • John J. Nicols (CEO and President)
  • Jim Lalonde (Vice President Research and Development)
  • Gordon Sangster (CFO)
Revenue Increase US$33-35 million (FY 2013)
Number of employees
88 (as of April 2014)
Website Codexis, Inc.

Codexis, Inc. is a leading protein engineering company that applies its revolutionary CodeEvolver platform technology to deliver high-performing enzymes for improving the cost and quality of pharmaceuticals and food ingredients, to enable sequencing of minute quantities of DNA for medical diagnostics, and to create novel biotherapeutics.

Codexis engineers custom enzymes and microorganisms, which are sometimes referred to as biocatalysts. Codexis' proprietary technology called CodeEvolver is directed evolution technology based on the concept that natural genetic mutation and selection can be accelerated in the research laboratory to obtain specific improvements in the function of single proteins and multiprotein pathways. CodeEvolver combines DNA shuffling and bioinformatics with systems biology to create new biocatalysts.

Codexis is using its work in biofuels to develop sustainable sources for the 2 million ton detergent alcohol market. Detergent alcohols go into household products such as shampoo and conditioner. Approximately 70% of detergent alcohols are derived from palm kernel oil. The remaining 30% is derived from petroleum. The rising price and price volatility of palm oil and crude oil combined with environmental concerns have prompted consumer product companies to seek out sustainable alternatives.

Codexis supplies varying quantities of its enzymes to pharmaceutical companies, from small to moderate quantities while they are optimizing their production processes, to larger quantities during later-stage clinical development and commercial scale drug production. Codexis also provides enzyme optimization services.

Customers can send Codexis their materials to test against Codexis’ existing libraries of enzymes. If Codexis detects desired activity in a specific enzyme, it can supply the customer with this enzyme or perform optimization services to improve the performance of the enzyme.

Codexis is based in Redwood City, CA and was incorporated in 2002. The company went public in April 2010 on NASDAQ.

Codexis won the Presidential Green Chemistry Challenge Award from the U.S. Environmental Protection Agency (EPA) in 2006 for its work on a building block of Lipitor and a second time with Merck in 2010 for its work on the active ingredient in Januvia.

Q reports

Period Date Adjusted Actuals EPS GAAP EPS
Q3 2020 2020-11-09 Future report Set alerts
Q2 2020 2020-08-06 -0.11 -0.11
Q1 2020 2020-05-07 -0.13 -0.13
Q4 2019 2020-02-27 -0.01 -0.01
Q3 2019 2019-11-05 0.01 0.01
Q2 2019 2019-08-06 -0.12 -0.12
Q1 2019 2019-05-06 -0.09 -0.09
Q4 2018 2019-02-26 -0.01 -0.01
Q3 2018 2018-11-08 -0.04 -0.04
Q2 2018 2018-08-08 -0.07 -0.07

Ratings

2016-06-01 Initiated Coverage HC Wainwright Buy $6.00
2016-05-10 Reiterated Rating HC Wainwright Buy
2016-02-13 Initiated Coverage HC Wainwright Buy
2016-01-06 Initiated Coverage HC Wainwright Buy $6.00
2015-04-15 Initiated Coverage First Analysis Overweight
2015-03-04 Downgrade Ladenburg Thalmann Buy to Neutral
2014-12-17 Initiated Coverage Craig Hallum Buy
2016-06-01 Initiated Coverage HC Wainwright Buy $6.00
2016-05-10 Reiterated Rating HC Wainwright Buy
2016-02-13 Initiated Coverage HC Wainwright Buy
2016-01-06 Initiated Coverage HC Wainwright Buy $6.00
2015-04-15 Initiated Coverage First Analysis Overweight

There is presents forecasts of rating agencies and recommendations for investors about this ticker

Major Shareholders

Name Relationship Total Shares Holding stocks
Ispagnac Participacoes Ltda. 14.24%  (5573319) CDXS /
Equilon Enterprises LLC 14.24%  (5573319) CDXS /
Shell Brazil Holding B.V. 14.24%  (5573319) CDXS /
NICOLS JOHN J President & CEO 2.74%  (1072679) CDXS /
MAXYGEN INC 1.34%  (524643) CDXS /
Yang Patrick Y 0.89%  (348234) AMRS / CDXS / CLDN / TSO /
Sheehy Douglas T. SVP, Gen Counsel and Sec. 0.63%  (247617) CDXS /
Lalonde James SVP, R&D 0.59%  (230066) CDXS /
KELLEY BERNARD J 0.59%  (229951) CDXS /
SHAW ALAN President and CEO 0.52%  (202000) CDXS /
Dorgan Byron L 0.50%  (194670) CDXS /
BARUCH THOMAS R 0.44%  (172170) CDXS / IMI /
SANGSTER GORDON SVP & Chief Financial Officer 0.44%  (171925) CDXS /
WOLF DENNIS P 0.30%  (116254) CDXS / FIO / QTM /
VIVO VENTURES VII, LLC 0.29%  (115321) CDXS / MEIP /
O'Toole David D SVP & Chief Financial Officer 0.28%  (110687) CAPN / CDXS / MNOV / RGDX /
Glaub Kathleen Sereda 0.26%  (102197) CDXS /
Cheng Pam P. 0.25%  (97934) CDXS /
Anton David L. SVP, Research and Development 0.24%  (93777) CDXS /
Seufer-Wasserthal Peter SVP, Pharmaceuticals 0.24%  (93064) CDXS /
Vivo Ventures Fund VII, L.P. 0.23%  (90330) CDXS /
Tobin Matthew SVP, Research & Development 0.20%  (78707) CDXS /
Karsner Alexander 0.20%  (78519) AMAT / CDXS /
Sarret Joseph J. CBO, President Pharmaceuticals 0.19%  (74000) CDXS /
Strumph Peter M Interim President and CEO 0.16%  (60756) CDXS /
Smith David V 0.14%  (56679) CDXS / OGXI /
Lawson Robert J SVP and CFO 0.11%  (44000) CDXS /
Dowd Brian Paul Interim CFO 0.07%  (28310) CDXS /
Pasternack Bruce A 0.03%  (10000) ACCL / CDXS /

Comments